Nuevas perspectivas clínicas en el uso de los anticoagulantes orales directos
- 1 February 2014
- journal article
- review article
- Published by Elsevier in Medicina Clinica
- Vol. 142 (4) , 171-178
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor XaJournal of Thrombosis and Haemostasis, 2011
- Drug and dietary interactions of warfarin and novel oral anticoagulants: an updateJournal of Thrombosis and Thrombolysis, 2011
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysJournal of Thrombosis and Haemostasis, 2011
- The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro studyJournal of Thrombosis and Haemostasis, 2010
- Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of ThrombinArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Drug and dietary interactions of the new and emerging oral anticoagulantsInternational Journal Of Clinical Practice, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assayThrombosis and Haemostasis, 2010
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007